Inhibiting EIF2AK1 could help treat sickle cell disease

Researchers from Children’s Hospital of Philadelphia and University of Pennsylvania showed that inhibiting EIF2AK1 to increase fetal hemoglobin could help treat sickle cell disease.

As genetic diseases such as SCD and some thalassemias affect patients only after red blood cells transition from fetal to adult hemoglobin production after birth, strategies to increase fetal hemoglobin are used to treat these hemoglobinopathies...